mRNA vaccines protect against severe infectious diseases, review confirms

Billions of mRNA vaccine doses administered globally confirm their safety and effectiveness against infectious diseases, including severe COVID-19, across all age groups and health conditions. Researchers emphasize that serious side effects are rare, with benefits far outweighing risks. This technology, now proven, holds immense promise for future vaccines and personalized treatments, though equitable global access remains crucial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZiMdsJ0
via IFTTT

Read More

Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discovery

Mankind Pharma has joined forces with Denovo Sciences to revolutionize drug discovery using artificial intelligence. This strategic partnership aims to significantly shorten development timelines, improve the quality of potential drug candidates, and identify the most promising options. By integrating AI with human expertise, the companies are set to accelerate the delivery of effective and accessible new medicines to patients, marking a significant step forward in pharmaceutical innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oHUbqxj
via IFTTT

Read More

Telangana plans drug discovery push to move Hyderabad up pharma value chain

Telangana is charting a new course to elevate Hyderabad into a global drug discovery hub. The state is fostering an integrated ecosystem by creating shared infrastructure and funding for startups and researchers. This ambitious plan aims to accelerate the development of next-generation therapies, including cell and gene therapies, by leveraging existing strengths and forging new partnerships, positioning Hyderabad for significant advancements in pharmaceutical innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Sxoj2Tm
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic acne treatment gel

Alembic Pharmaceuticals has secured final USFDA approval for its generic Dapsone gel, a topical treatment for acne vulgaris. This approval, for the 5% strength, means the company can now market its version, which is therapeutically equivalent to Almirall's Aczone Gel. This development marks a significant step for Alembic in the US market, offering a new option for acne sufferers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nMls3jE
via IFTTT

Read More

India’s nutraceutical market set to nearly double to $57 billion by 2030 on preventive health boom

India's health-conscious population is fueling a boom in the nutraceutical market, projected to nearly double to $55-57 billion by 2030. This shift towards preventive care, supported by e-commerce and government initiatives, sees the sector growing at an impressive 10.5% CAGR. While regulatory efforts are strengthening, challenges like consumer awareness and scientific validation persist, yet the industry is poised for significant expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Na4JrkL
via IFTTT

Read More

Health ministry proposes faster approvals for medical device manufacturing licences

The Union health ministry is proposing to significantly cut down the time taken to issue manufacturing licenses for medical devices. Aimed at boosting ease of doing business and ensuring quicker access to quality products, the amendments will reduce timelines for low to high-risk devices. For instance, Class B devices will see a reduction from 140 to 115 days, and high-risk Class C and D devices from 105 to 90 days.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O2VZyaD
via IFTTT

Read More

Strides Pharma sells majority stake in arm Pivot Path for Rs 100 crore

Strides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital and Vintage Classic. This strategic move aims to accelerate Pivot Path's growth by infusing Rs 50 crore for future expansion. Strides will retain a 19.95% stake, while the investors will hold 65.05%. The transaction values Pivot Path at Rs 230 crore post-money.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Th4cZFf
via IFTTT

Read More